Half of the KRAS-mutant NSCLC (non-small-cell lung cancers) express the homeobox protein HOXC10, which triggered tumour regression in xenografts and PDX (patient-derived xenografts) models in vivo [31]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.